-
Mashup Score: 7Common Sense Oncology Outlines 9 Core Clinical Trial Principles - 12 day(s) ago
Leaders of the Common Sense Oncology initiative, launched 1.5 years ago as “a new patient-centered movement in cancer care,” outline principles for trial design, analysis, and reporting.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1CBC Listen Media Player - 12 day(s) ago
Calgary Edmonton Kamloops Kelowna Prince George Vancouver Victoria Winnipeg Fredericton Moncton Saint John Corner Brook Goose Bay Grand Falls St. John’s Inuvik Yellowknife Halifax Sydney Iqaluit Kenora Barrie Kingston Kitchener-Waterloo London Ottawa Peterborough Sudbury Thunder Bay Toronto Windsor Charlottetown Montreal North Quebec Quebec City Regina Saskatoon Whitehorse
Source: www.cbc.caCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials - 14 day(s) ago
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of randomised, controlled, phase 3 clinical trials evaluating cancer treatments. These principles include: (1) control treatment should be the best current standard of care; (2) the preferred primary endpoint is overall survival or a validated surrogate; (3) an absolute measure of benefit should be provided, such as the difference between groups in median overall survival times or the proportion of surviving patients at a prespecified time; (4) health-related quality of life should be at least a secondary endpoint; (5) toxicity should be described objectively without subjective language diminishing its importance; (6) trials should be designed to show or rule out clinically meaningful differences in outcomes, rather than a statistically significant difference alone; (7) censoring should be detail
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19A checklist for designing and reporting cancer drug phase 3 clinical trials - ecancer - 14 day(s) ago
Dr Bishal Gyawali talks to ecancer about a checklist for reporting of phase 3 randomised controlled trials of cancer drugs. The checklist, developed by Commo
Source: ecancer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42ESMO 2024: Highlights and analysis - ecancer - 21 day(s) ago
Asst. Prof Bishal Gyawali talks to ecancer at the 2024 ESMO Congress about his highlights from this year’s conference.
Source: ecancer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint - OncoDaily - 21 day(s) ago
Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint / Bishal Gyawali, cancer, fight against cancer, Global fight against cancer,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Bishal Gyawali: Skills Lab - Clinical Trial Methods - Focus on the Control Arm - OncoDaily - 23 day(s) ago
Bishal Gyawali: Skills Lab – Clinical Trial Methods – Focus on the Control Arm / Bishal Gyawali, cancer, clinical trial, fight against cancer, Global fight
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Skills Lab: Clinical Trial Methods — Focus on the Control Arm - 26 day(s) ago
Dr Bishal Gyawali discusses the methods section of clinical trial publications, focusing on potential issues with the control arm.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 109Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial - 1 month(s) ago
View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Thank you @Medscape for this excellent coverage of our recent publication of CSO Checklist for design and reporting of cancer drug RCTs. https://t.co/z8kcmcifXK